Come up with a name for your new list and we'll add to it:
Modulate Therapeutics raised a round of funding on February 01, 2016. Investors include
TVM Capital Life Science.
Modulate Therapeutics plans to develop, to proof-of-concept, the compound IMM-01 that is designed to re-engage the immune system in order to recognize and eradicate neoplastic disease.…